Adaptive Biotechnologies ... (ADPT)
8.46
-0.20 (-2.31%)
At close: Mar 25, 2025, 3:59 PM
8.42
-0.41%
Pre-market: Mar 26, 2025, 07:10 AM EDT
-2.31% (1D)
| Bid | 8.37 |
| Market Cap | 1.26B |
| Revenue (ttm) | 180.76M |
| Net Income (ttm) | -161.1M |
| EPS (ttm) | -1.08 |
| PE Ratio (ttm) | -7.83 |
| Forward PE | -9.1 |
| Analyst | Buy |
| Ask | 8.7 |
| Volume | 1,243,557 |
| Avg. Volume (20D) | 1,700,093 |
| Open | 8.59 |
| Previous Close | 8.66 |
| Day's Range | 8.38 - 8.75 |
| 52-Week Range | 2.28 - 9.01 |
| Beta | 1.53 |
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a cli...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 619
Stock Exchange NASDAQ
Ticker Symbol ADPT
Website https://www.adaptivebiotech.com
Analyst Forecast
According to 5 analyst ratings, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 6.45% from the latest price.
Stock ForecastsNext Earnings Release
Adaptive Biotechnologies Corporation is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-3.21%
Adaptive Biotechnologies shares are trading lower....
Unlock content with
Pro Subscription
4 months ago
+11.51%
Adaptive Biotechnologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7.
